Review Article

You have full text access to this OnlineOpen article

Maintenance therapy in nonsmall-cell lung cancer†

A new treatment paradigm

  1. Tony S. K. Mok MD1,‡,*,
  2. Suresh S. Ramalingam MD2

Article first published online: 5 AUG 2009

DOI: 10.1002/cncr.24563

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5143–5154, 15 November 2009

Additional Information

How to Cite

Mok, T. S. K. and Ramalingam, S. S. (2009), Maintenance therapy in nonsmall-cell lung cancer. Cancer, 115: 5143–5154. doi: 10.1002/cncr.24563

Author Information

  1. 1

    Department of Clinical Oncology, Sir Y. K. Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Hong Kong, China

  2. 2

    Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia

  1. ‡

    Fax: (011) 852 2648 7097

*Department of Clinical Oncology, Sir Y. K. Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China

  1. †

    The authors take full responsibility for the content of the paper but thank Huzefa Photowala, PhD from Gardiner-Caldwell Communications, supported by Genentech Inc, OSI Pharmaceuticals Inc, and F. Hoffmann-La Roche Ltd, for his assistance in organizing the published literature, preparing the initial draft of the manuscript, and collating the comments of authors.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 5 AUG 2009
  3. Manuscript Accepted: 10 APR 2009
  4. Manuscript Revised: 8 APR 2009
  5. Manuscript Received: 21 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (173K)

References

  • 1
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 2
    Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist. 2007; 12: 451-464.
  • 3
    Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979; 63: 1727-1733.
  • 4
    Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52: 155-163.
  • 5
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330-353.
  • 6
    National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed November 12, 2008.
  • 7
    Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of 3 versus 6 courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19: 1336-1343.
  • 8
    Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20: 1335-1343.
  • 9
    Park JO, Kim SW, Ahn JS, et al. Phase III trial of 2 versus 4 additional cycles in patients who are nonprogressive after 2 cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25: 5233-5239.
  • 10
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095-2103.
  • 11
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
  • 12
    Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl. J Med. 2005; 353: 123-132.
  • 13
    Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol. 2007; 25: 5155-5157.
  • 14
    Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21: 2933-2939.
  • 15
    Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26: 468-473.
  • 16
    Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 499-506.
  • 17
    Taxotere Package Insert. Available at: http://products.sanofi-aventis.us/Taxotere/taxotere.html. Accessed November 12, 2008.
  • 18
    Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival [abstract]. J Clin Oncol. 2007; 25: 388s.
  • 19
    Alimta Package Insert. Available at: http://pi.lilly.com/us/alimta-pi.pdf. Accessed November 12, 2008.
  • 20
    Ciuleanu T, Brodowicz T, Belani C, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study [abstract]. J Clin Oncol. 2008; 26: 426s.
  • 21
    Soon Y, Stockler M, Boyer M, Askie L. Duration of chemotherapy for advanced non-small cell lung cancer: an updated systematic review and meta-analysis [abstract]. J Clin Oncol. 2008; 26: 427s.
  • 22
    Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs. 2007; 67: 1125-1138.
  • 23
    Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr Opin Oncol. 2008; 20: 176-182.
  • 24
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
  • 25
    Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract]. J Clin Oncol. 2007; 25: 388s.
  • 26
    Manegold C, von Pawel J, Zatloukal P, et al. BO17704 (AVAiL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC) [abstract]. Ann Oncol. 2008; 19: viii1.
  • 27
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
  • 28
    Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 1545-1552.
  • 29
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol. 2004; 22: 785-794.
  • 30
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol. 2004; 22: 777-784.
  • 31
    Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol. 2005; 23: 5856-5858.
  • 32
    Xu JM, Azzariti A, Colucci G, Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol. 2003; 52: 442-448.
  • 33
    Davies AM, Ho C, Lara PN, Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006; 7: 385-388.
  • 34
    Lee J, Ignacio J, Yu C, et al. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008; 26: 431s.
  • 35
    Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG) [abstract]. J Clin Oncol. 2008; 26: 427s.
  • 36
    Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26: 2450-2456.
  • 37
    Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008; 13 suppl 1: 28-36.
  • 38
    Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2006; 24: 3831-3837.
  • 39
    Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 61: 405-415.
  • 40
    Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 26: 2008( suppl). Abstract 19000.
  • 41
    Clinical Trial NCT00556712. A study of tarceva (erlotinib) following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC (SATURN). Available at: http://www.clinicaltrials.gov/ct/show/NCT00556712. Accessed November 12, 2008.
  • 42
    Roche press release. Available at: http://www.roche.com/media/media_releases/med-cor-2008-11-07.htm. Accessed November 12, 2008.
  • 43
    Clinical Trial NCT00257608. A study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (ATLAS). Available at: http://www.clinicaltrials.gov/ct/show/NCT00257608. Accessed November 12, 2008.
  • 44
    Roche press release. Available at http://www.roche.com/media/media_releases/med-cor-2009-02-03.htm Accessed February 4, 2009.
  • 45
    Clinical trial endpoints for the approval of cancer drugs and biologics. Available at: http://www.fda.gov/cber/gdlns/clintrialend.htm. Accessed November 12, 2008.
  • 46
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
  • 47
    Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol. 2008; 19( suppl 8): viii1-viii4.
  • 48
    Freidlin B, Korn EL, Hunsberger S, et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007; 25: 2122-2126.
View Full Article (HTML) Get PDF (173K)